SEK 10.08
(0.4%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -122.02 Million SEK | -0.32% |
2022 | -89.4 Million SEK | -0.65% |
2021 | -83.95 Million SEK | -3.38% |
2020 | -80.63 Million SEK | 2.61% |
2019 | -81.6 Million SEK | -71.31% |
2018 | -47.9 Million SEK | -20.44% |
2017 | -38.57 Million SEK | -0.36% |
2016 | -36.29 Million SEK | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -12.03 Million SEK | 100.0% |
2024 Q2 | -15.29 Million SEK | 0.0% |
2023 Q4 | -64.06 Million SEK | -257.67% |
2023 FY | - SEK | -0.32% |
2023 Q1 | -21.3 Million SEK | -5.8% |
2023 Q2 | -17.55 Million SEK | 17.61% |
2023 Q3 | -17.91 Million SEK | -2.04% |
2022 Q3 | -17.21 Million SEK | 21.04% |
2022 Q2 | -21.79 Million SEK | -1.32% |
2022 FY | - SEK | -0.65% |
2022 Q4 | -20.13 Million SEK | -16.99% |
2022 Q1 | -21.51 Million SEK | 3.89% |
2021 FY | - SEK | -3.38% |
2021 Q4 | -22.38 Million SEK | -59.81% |
2021 Q3 | -14 Million SEK | 36.31% |
2021 Q2 | -21.99 Million SEK | -1.78% |
2021 Q1 | -21.6 Million SEK | 4.09% |
2020 Q4 | -22.52 Million SEK | -33.62% |
2020 Q3 | -16.86 Million SEK | 20.73% |
2020 FY | - SEK | 2.61% |
2020 Q1 | -17.09 Million SEK | 38.39% |
2020 Q2 | -21.26 Million SEK | -24.44% |
2019 Q1 | -15.7 Million SEK | -5.68% |
2019 FY | - SEK | -71.31% |
2019 Q4 | -27.74 Million SEK | -51.14% |
2019 Q3 | -18.35 Million SEK | -5.22% |
2019 Q2 | -17.44 Million SEK | -11.07% |
2018 Q3 | -11.03 Million SEK | -8.77% |
2018 Q2 | -10.14 Million SEK | 1.83% |
2018 Q1 | -10.33 Million SEK | 0.0% |
2018 FY | - SEK | -20.44% |
2018 Q4 | -14.86 Million SEK | -34.76% |
2017 FY | - SEK | -0.36% |
2016 FY | - SEK | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Acarix AB (publ) | -77.12 Million SEK | -58.218% |
ADDvise Group AB (publ) | 411.9 Million SEK | 129.624% |
ADDvise Group AB (publ) | 411.9 Million SEK | 129.624% |
Arcoma AB | 6.24 Million SEK | 2052.961% |
Bactiguard Holding AB (publ) | -89.98 Million SEK | -35.606% |
BICO Group AB (publ) | 322.3 Million SEK | 137.859% |
Boule Diagnostics AB (publ) | 65.97 Million SEK | 284.939% |
CellaVision AB (publ) | 207.24 Million SEK | 158.878% |
Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | -78.378% |
Chordate Medical Holding AB (publ) | -27.94 Million SEK | -336.678% |
C-Rad AB (publ) | 48.9 Million SEK | 349.511% |
Duearity AB (publ) | -24.77 Million SEK | -392.437% |
Dignitana AB (publ) | -264 Thousand SEK | -46120.076% |
Episurf Medical AB (publ) | -87.7 Million SEK | -39.135% |
Getinge AB (publ) | 5.92 Billion SEK | 102.058% |
Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | -81.444% |
Iconovo AB (publ) | -35.33 Million SEK | -245.322% |
Integrum AB (publ) | 8.76 Million SEK | 1492.691% |
Luxbright AB (publ) | -23.86 Million SEK | -411.26% |
Mentice AB (publ) | 28.87 Million SEK | 522.613% |
Paxman AB (publ) | 31.22 Million SEK | 490.73% |
Promimic AB (publ) | -3.68 Million SEK | -3212.189% |
Qlife Holding AB (publ) | -150.5 Million SEK | 18.926% |
SciBase Holding AB (publ) | -51.82 Million SEK | -135.43% |
ScandiDos AB (publ) | -13.35 Million SEK | -813.604% |
Sectra AB (publ) | 615.06 Million SEK | 119.839% |
Sedana Medical AB (publ) | -51.67 Million SEK | -136.136% |
Senzime AB (publ) | -118.82 Million SEK | -2.691% |
SpectraCure AB (publ) | -20.96 Million SEK | -481.911% |
Stille AB | 56.04 Million SEK | 317.735% |
Vitrolife AB (publ) | -3.18 Billion SEK | 96.169% |
Xvivo Perfusion AB (publ) | 126.57 Million SEK | 196.403% |